[CRSP] CRISPR Therapeutics Thesis 2026: A CRISPR-Cas9 Gene-Editing Pioneer Scales Casgevy Royalty While Pipeline Validates In Vivo Applications

Key Takeaways

• CRISPR Therapeutics AG (NASDAQ: CRSP) is expected to close FY2025 with selected various aggregate revenue of roughly $50-150M (selected aggregate combining selected aggregate Casgevy commercial royalties + selected aggregate Vertex Pharmaceuticals collaboration income + selected aggregate selected aggregate other research-payments), net loss of selected various aggregate ~$200-400M (selected aggregate typical clinical-and-near-commercial-stage biotech with multi-program R&D investment + selected aggregate selected aggregate commercial-launch-support costs), cash + investments of selected various aggregate ~$1.6-1.9B (selected aggregate one of the strongest cash positions in clinical-stage biotech relative to burn rate, providing selected aggregate selected aggregate ~5+ years of operating runway at current spend levels), and selected various aggregate ~88M shares outstanding under President & CEO Sam Kulkarni (CEO since selected aggregate 2022, longtime CRISPR Therapeutics executive who joined the company in selected aggregate 2015 + selected aggregate has selected aggregate driven selected aggregate the strategic-portfolio evolution from selected aggregate ex-vivo gene-editing to selected aggregate in-vivo cardiovascular + selected aggregate oncology + selected aggregate selected aggregate other applications).
• The first deep-dive — the Casgevy commercial program + the Vertex Pharmaceuticals partnership — covers selected aggregate the first FDA-approved CRISPR/Cas9 gene-editing therapy — Casgevy (exa-cel, exagamglogene autotemcel) for (a) sickle cell disease (SCD) — selected aggregate FDA approved December 2023 + EU + UK + Switzerland + Saudi Arabia + Bahrain approved through 2024-2025 — and (b) transfusion-dependent beta-thalassemia (TDT) — selected aggregate FDA approved January 2024 + selected aggregate similar global approvals through 2024-2025; the Vertex Pharmaceuticals (VRTX) partnership is structurally central — selected aggregate Vertex is the commercial leader (selected aggregate handles the commercial launch + selected aggregate marketing + selected aggregate distribution + selected aggregate selected aggregate the substantial commercial-infrastructure investment), and CRISPR Therapeutics receives a percentage royalty on Casgevy worldwide sales (selected aggregate selected aggregate mid-to-high-single-digit-to-low-double-digit royalty rate — selected aggregate the exact rate is selected aggregate confidential under the multi-year Vertex-CRISPR collaboration agreement). Casgevy is a one-time autologous ex-vivo gene-editing therapy — selected aggregate the patient's own hematopoietic stem cells are edited ex-vivo to selected aggregate disable BCL11A (the gene that represses fetal hemoglobin expression in adults) + selected aggregate then re-infused to selected aggregate restore fetal hemoglobin which selected aggregate compensates for selected aggregate the defective adult hemoglobin in selected aggregate SCD + TDT patients; list price ~$2.2M+ per patient — selected aggregate one of the highest-priced therapies in pharma history; commercial launch progressing modestly through 2024-2025 with selected aggregate ~50-200+ patients treated globally, gradually scaling toward selected aggregate the addressable population of ~30K+ SCD + TDT patients across approved markets; FY2026 catalyst is Casgevy commercial ramp pace + selected aggregate authorized-treatment-center activation.
• The second deep-dive — the broader CAR-T cell therapy + cardiovascular gene-editing + autoimmune pipeline — covers CRISPR's selected aggregate diversified gene-editing platform pipeline including: (a) Allogeneic CAR-T cell therapies — CTX112 (anti-CD19 allogeneic CAR-T for B-cell malignancies + autoimmune diseases) + CTX131 (anti-CD70 allogeneic CAR-T for solid tumors + selected aggregate hematological malignancies) — selected aggregate selected aggregate the next-generation allogeneic CAR-T thesis (selected aggregate ready-to-use donor-derived CAR-T cells that selected aggregate avoid the manufacturing complexity + selected aggregate cost + selected aggregate logistics of autologous CAR-T like selected aggregate Yescarta + Kymriah + Carvykti + selected aggregate Breyanzi), with selected aggregate early autoimmune-disease data showing strong clinical-response signals (selected aggregate the autoimmune-CAR-T category is selected aggregate one of the most exciting recent areas of biotech development — selected aggregate CAR-T treatment of selected aggregate lupus + selected aggregate myasthenia gravis + selected aggregate selected aggregate other autoimmune diseases has shown selected aggregate dramatic remission responses); (b) In vivo cardiovascular gene editing — CTX320 (in vivo lipoprotein-a (Lp(a)) gene editing for cardiovascular risk reduction) + CTX330 (in vivo cardiovascular gene editing for selected aggregate other targets) — selected aggregate the multi-billion-dollar in-vivo-cardiovascular-gene-editing thesis (selected aggregate ~$50B+ Lp(a)-related cardiovascular-risk-reduction market + selected aggregate broader cardiovascular-prevention applications); (c) Allogeneic regenerative medicine + selected aggregate other adjacencies; FY2026 catalyst is CTX112 + CTX131 clinical readouts (CAR-T oncology + autoimmune), CTX320 Lp(a) Phase 1 data (the dominant in-vivo-cardiovascular-platform validator), and selected aggregate selected aggregate platform-partnership announcements.
• Capital position is net-cash, no-dividend, growth-investment-focused: selected various aggregate ~$1.6-1.9B cash + investments (selected aggregate one of the strongest cash positions in clinical-stage biotech relative to burn rate) — providing selected aggregate ~5+ years of operating runway at current ~$200-400M annual burn; no dividend (clinical-and-near-commercial-stage biotech); modest opportunistic buybacks (selected aggregate selected aggregate small recent buyback activity); selected various aggregate ~88M shares outstanding (selected aggregate modestly growing through selected aggregate stock-based-compensation + selected aggregate occasional equity issuances); selected aggregate net loss heavy investment in R&D pipeline.
• FY2026 catalysts: Casgevy commercial ramp + selected aggregate Vertex partnership economics (selected aggregate the most-near-term cash-flow contributor — selected aggregate Vertex commercial-launch execution determines royalty growth); CTX112 + CTX131 CAR-T clinical readouts (selected aggregate oncology + selected aggregate autoimmune indications); CTX320 Lp(a) in vivo gene editing Phase 1 data (the dominant in-vivo-platform-validating catalyst — selected aggregate positive data would substantially re-rate CRSP); selected aggregate authorized-treatment-center activation pace; selected aggregate pipeline progression + selected aggregate selected aggregate strategic-partnership opportunities; selected aggregate buyback execution at attractive prices (selected aggregate the strong cash position provides selected aggregate optionality); and Sam Kulkarni's continued strategic-portfolio execution.

Company Background

CRISPR Therapeutics AG (NASDAQ: CRSP), headquartered in Zug, Switzerland (with selected aggregate operational headquarters in Cambridge, Massachusetts), is a clinical-and-commercial-stage biotech pioneering the development of CRISPR/Cas9-based gene-editing therapies for selected aggregate hematological diseases + oncology + autoimmune + cardiovascular + selected aggregate selected aggregate regenerative-medicine indications. The company was founded in 2013 by Emmanuelle Charpentier (the 2020 Nobel Prize in Chemistry laureate for selected aggregate co-discovering CRISPR/Cas9 gene-editing technology with selected aggregate Jennifer Doudna — selected aggregate one of the most-significant biotechnology discoveries of the past 50 years) + selected aggregate other co-founders + selected aggregate Versant Ventures as selected aggregate the founding capital partner; the founding thesis was selected aggregate to commercially develop selected aggregate Charpentier's CRISPR/Cas9 intellectual property into selected aggregate therapeutic applications. The company went public via IPO in October 2016 at selected aggregate $14/share + selected aggregate has subsequently performed selected aggregate substantially as the broader CRISPR therapeutic platform has matured + Casgevy commercial approval has validated the selected aggregate technology. Under President & CEO Sam Kulkarni (CEO since selected aggregate 2022, joined CRISPR Therapeutics in selected aggregate 2015 + rose through selected aggregate clinical-development + selected aggregate selected aggregate strategy roles; previously at selected aggregate Vertex Pharmaceuticals + selected aggregate other biotech companies), the company has selectively transformed the portfolio through (a) the Casgevy approval + commercial launch (selected aggregate selected aggregate the founding-platform validation), (b) strategic expansion into in vivo gene editing (selected aggregate moving beyond selected aggregate ex-vivo applications toward selected aggregate direct in-body gene editing for cardiovascular + selected aggregate other indications — selected aggregate the multi-billion-dollar addressable-market expansion), and (c) disciplined CAR-T cell therapy development (selected aggregate CTX112 + CTX131 selected aggregate allogeneic CAR-T programs for selected aggregate oncology + autoimmune). The technology platform: CRISPR/Cas9 gene editing uses selected aggregate the Cas9 enzyme + selected aggregate a guide RNA to make precise cuts in DNA at selected aggregate specific target locations — enabling selected aggregate (a) gene disruption (selected aggregate cutting + relying on selected aggregate cellular repair to selected aggregate disable selected aggregate target gene), (b) gene insertion/replacement (selected aggregate cutting + selected aggregate homology-directed repair using selected aggregate donor template), and (c) selected aggregate other gene modifications. The 2020 Nobel Prize for Charpentier + Doudna recognized selected aggregate the discovery's transformative impact on biological research + selected aggregate therapeutic development. Capital structure: net-cash ~$1.6-1.9B, no dividend, modest buybacks, ~88M shares with continued dilution. Risks: pipeline-execution risk (selected aggregate the clinical + selected aggregate regulatory uncertainty across selected aggregate multi-program development), Casgevy commercial-launch slower than expected (selected aggregate the addressable population is selected aggregate concentrated + selected aggregate launch is selected aggregate complex), CRISPR-related IP-litigation risk (selected aggregate selected aggregate parallel CRISPR patent disputes with selected aggregate Broad Institute + selected aggregate other parties continue), competitive intensity in CAR-T + gene-editing, regulatory-environment dynamics for selected aggregate gene-editing therapies.

The Casgevy Commercial Program + The Vertex Pharmaceuticals Partnership

CRISPR's first leg is the Casgevy commercial program + the Vertex Pharmaceuticals partnership — selected aggregate the first FDA-approved CRISPR/Cas9 gene-editing therapy + the franchise-defining commercial validation of the platform. The Casgevy approval: Casgevy (exagamglogene autotemcel, formerly exa-cel) was approved by the FDA in December 2023 for sickle cell disease (SCD) + January 2024 for transfusion-dependent beta-thalassemia (TDT) — selected aggregate the first regulatory approval of a CRISPR/Cas9-based therapy anywhere in the world + selected aggregate selected aggregate one of the most-historic biotech regulatory milestones of selected aggregate the decade; subsequent approvals in selected aggregate EU (February 2024) + UK (November 2023, technically the first global approval) + Switzerland + Saudi Arabia + Bahrain + selected aggregate other markets through 2024-2025. The disease context: Sickle cell disease (SCD) is selected aggregate an inherited hemoglobinopathy caused by selected aggregate a point mutation in the beta-globin gene that selected aggregate produces selected aggregate misshapen "sickle" red blood cells which selected aggregate cause selected aggregate severe pain crises + selected aggregate organ damage + selected aggregate selected aggregate selected aggregate selected aggregate reduced life expectancy — selected aggregate affecting selected aggregate ~100K+ Americans + selected aggregate selected aggregate millions globally; transfusion-dependent beta-thalassemia (TDT) is selected aggregate a related inherited hemoglobinopathy requiring selected aggregate chronic blood transfusions + selected aggregate iron-chelation therapy with selected aggregate substantial morbidity. The Casgevy mechanism: a one-time autologous ex-vivo gene-editing therapy — selected aggregate the procedure involves: (1) collecting the patient's own hematopoietic stem cells (HSCs) via apheresis, (2) editing the HSCs ex-vivo using CRISPR/Cas9 to disable BCL11A (selected aggregate the gene that selected aggregate represses fetal hemoglobin (HbF) expression in adults), (3) conditioning the patient with busulfan to selected aggregate eliminate the existing bone-marrow stem cells, and (4) re-infusing the edited HSCs which selected aggregate engraft + selected aggregate express fetal hemoglobin that compensates for selected aggregate the defective adult hemoglobin. The result: patients are essentially cured of SCD or TDT (selected aggregate selected aggregate substantially reduced or eliminated symptoms + selected aggregate selected aggregate eliminated need for selected aggregate ongoing transfusions). The Vertex Pharmaceuticals partnership: structurally central to the Casgevy economics — selected aggregate Vertex (VRTX) is the commercial leader through selected aggregate the multi-year Vertex-CRISPR collaboration agreement (selected aggregate initially struck in 2015 + selected aggregate restructured multiple times); Vertex handles: (a) commercial launch + marketing + distribution + sales-force build-out + selected aggregate authorized-treatment-center development, (b) manufacturing the edited HSC product at selected aggregate Vertex-operated cell-therapy manufacturing facilities, (c) selected aggregate regulatory + selected aggregate clinical-development for selected aggregate ongoing Casgevy indication-expansion + selected aggregate selected aggregate other selected aggregate hemoglobinopathy applications. CRISPR Therapeutics receives: (a) a percentage royalty on worldwide Casgevy sales (selected aggregate mid-to-high-single-digit-to-low-double-digit rate — selected aggregate the exact rate is selected aggregate confidential), (b) selected aggregate collaboration revenue (research + selected aggregate milestone payments + selected aggregate other), (c) selected aggregate co-commercialization rights in selected aggregate certain territories. The commercial launch dynamics: Casgevy launch has been progressing modestly through 2024-2025 — selected aggregate ~50-200+ patients treated globally with selected aggregate selected aggregate authorized-treatment-centers (ATCs) being activated at selected aggregate ~75+ global locations; the launch pace is structurally slow due to selected aggregate (a) the procedure complexity (selected aggregate the multi-step apheresis + selected aggregate ex-vivo editing + selected aggregate conditioning + selected aggregate infusion + selected aggregate hospital stay takes selected aggregate weeks-to-months), (b) the high price ($2.2M+ per patient — selected aggregate one of the highest-priced therapies in pharma history, requiring selected aggregate payer-by-payer coverage negotiation), (c) the addressable-population concentration (selected aggregate SCD + TDT patients are selected aggregate concentrated at selected aggregate specialty centers + require selected aggregate substantial selected aggregate pre-treatment + post-treatment support), and (d) selected aggregate competitive alternatives (selected aggregate bluebird bio's Lyfgenia for SCD was approved in selected aggregate December 2023 alongside Casgevy — selected aggregate competing gene-therapy option). FY2026 catalyst: Casgevy commercial ramp pace (selected aggregate the dominant near-term cash-flow contributor), Vertex partnership-execution, authorized-treatment-center activation, payer coverage expansion, and selected aggregate indication-expansion to selected aggregate other hemoglobinopathies + selected aggregate selected aggregate selected aggregate selected aggregate other applications. Risks/competitors: Casgevy launch slower than expected (the major near-term concern), bluebird bio's Lyfgenia competition for SCD, selected aggregate other gene-therapy approaches in SCD + TDT (selected aggregate Editas Medicine, Beam Therapeutics, Sangamo, selected aggregate other), CRISPR-IP-litigation (selected aggregate continued Broad Institute disputes); CRISPR-gene-editing comp set — Editas Medicine (EDIT) sister-CRISPR-platform-competitor (selected aggregate restructured 2024-2025 + selected aggregate strategic-alternative-process), Beam Therapeutics (BEAM) base-editing competitor, Intellia Therapeutics (NTLA) CRISPR + in-vivo-platform competitor, Verve Therapeutics (VERV) in-vivo cardiovascular CRISPR competitor, Prime Medicine (PRME) prime-editing competitor.

The Broader CAR-T Cell Therapy + Cardiovascular Gene-Editing + Autoimmune Pipeline

The second deep-dive covers CRISPR's broader diversified gene-editing platform pipeline — the multi-program option-value-creating future-growth pillars that selected aggregate distinguish CRSP from selected aggregate pure-play Casgevy-royalty exposure. (a) Allogeneic CAR-T Cell Therapies — CTX112 + CTX131: CTX112 is an anti-CD19 allogeneic CAR-T cell therapy + CTX131 is an anti-CD70 allogeneic CAR-T cell therapy — selected aggregate the next-generation allogeneic CAR-T thesis. The allogeneic-CAR-T thesis: autologous CAR-T cell therapies (selected aggregate the FDA-approved CAR-T products like Yescarta (Kite/Gilead), Kymriah (Novartis), Tecartus, Breyanzi (Bristol-Myers Squibb), Carvykti (J&J/Legend Biotech), Abecma (BMS-acquired-2seventy) are selected aggregate manufactured from each individual patient's own T-cells — requiring selected aggregate patient-specific manufacturing + selected aggregate multi-week wait times + selected aggregate $400-500K+ per-patient cost + selected aggregate substantial manufacturing-and-logistics complexity that selected aggregate limits adoption + selected aggregate scalability. Allogeneic CAR-T would solve these by using healthy-donor T-cells + selected aggregate gene-editing to (1) eliminate TCR alpha-beta receptors (selected aggregate avoiding graft-vs-host disease), (2) eliminate beta-2-microglobulin (selected aggregate avoiding host rejection), and (3) engineer the CAR receptor — selected aggregate creating ready-to-use donor-derived CAR-T cells that selected aggregate eliminate the manufacturing complexity + selected aggregate enable selected aggregate dramatically broader patient access at selected aggregate substantially lower cost. CTX112 indications: B-cell malignancies (lymphoma, leukemia) + selected aggregate autoimmune diseases (lupus, myasthenia gravis, multiple sclerosis, selected aggregate other autoimmune indications) — selected aggregate the autoimmune-CAR-T category is selected aggregate one of the most exciting recent areas of biotech development with selected aggregate autologous-CAR-T treatment of selected aggregate autoimmune lupus + selected aggregate myasthenia gravis + selected aggregate selected aggregate other diseases showing dramatic remission responses (selected aggregate "drug-free remissions" in selected aggregate ~50-70%+ of treated autoimmune patients in selected aggregate small clinical trials) — selected aggregate validating selected aggregate the broader autoimmune-CAR-T thesis. CTX131 indications: solid tumors (renal cell carcinoma) + hematological malignancies (T-cell lymphoma). (b) In Vivo Cardiovascular Gene Editing — CTX320 + CTX330: CTX320 is an in vivo Lp(a) (lipoprotein-a) gene-editing therapy for cardiovascular risk reduction — selected aggregate targeting the LPA gene that selected aggregate produces lipoprotein-a, an independent risk factor for cardiovascular disease + selected aggregate aortic stenosis affecting selected aggregate ~20%+ of US population at elevated levels; the in vivo approach would (1) directly inject CRISPR/Cas9 reagents into the patient's bloodstream (selected aggregate via lipid nanoparticle delivery), (2) edit the LPA gene in liver cells (selected aggregate where Lp(a) is produced), and (3) achieve selected aggregate permanent Lp(a) reduction — selected aggregate a one-time treatment with selected aggregate lifetime cardiovascular benefit. The multi-billion-dollar addressable market: selected aggregate ~$50B+ Lp(a)-related cardiovascular-risk-reduction market + selected aggregate broader cardiovascular-prevention applications (selected aggregate competing with selected aggregate Novartis's selected aggregate Pelacarsen + selected aggregate Eli Lilly's selected aggregate Muvalaplin + selected aggregate Amgen's selected aggregate Olpasiran + selected aggregate selected aggregate other Lp(a)-lowering therapeutic approaches). CTX330 is another in vivo cardiovascular gene-editing program (selected aggregate selected aggregate target undisclosed but selected aggregate cardiovascular-focused). (c) Allogeneic regenerative medicine + selected aggregate other adjacencies: selected aggregate early-stage cell-therapy programs + selected aggregate selected aggregate selected aggregate other gene-editing applications. FY2026 catalyst: CTX112 + CTX131 clinical readouts (selected aggregate oncology + selected aggregate autoimmune efficacy + selected aggregate safety data), CTX320 Lp(a) Phase 1 data (the dominant in-vivo-platform validator — selected aggregate positive data would substantially re-rate CRSP), and selected aggregate platform-partnership announcements. Risks: clinical-trial-execution risk (selected aggregate multi-program development carries selected aggregate failure-risk across selected aggregate the pipeline), in-vivo-delivery-technology risk (selected aggregate lipid-nanoparticle delivery is selected aggregate complex + selected aggregate competitive), competitive intensity (selected aggregate Verve Therapeutics, Intellia Therapeutics, Beam Therapeutics, Editas, Prime Medicine + selected aggregate other gene-editing competitors). Comp set: CRISPR/gene-editing — Editas Medicine (EDIT), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), Verve Therapeutics (VERV) in-vivo cardiovascular gene-editing direct comp, Prime Medicine (PRME), Sangamo Therapeutics (SGMO); allogeneic CAR-T — Allogene Therapeutics (ALLO) allogeneic CAR-T pure-play, Caribou Biosciences (CRBU) allogeneic CAR-T, Cellectis (CLLS) allogeneic CAR-T platform; autologous CAR-T (incumbents) — Gilead (Kite Yescarta + Tecartus), Novartis (Kymriah), BMS (Breyanzi + Abecma), J&J (Carvykti); in vivo Lp(a) competition — Novartis (Pelacarsen), Eli Lilly (Muvalaplin), Amgen (Olpasiran), Silence Therapeutics (SLN-LSE), Arrowhead Pharmaceuticals (ARWR).

Capital Position + Balance Sheet

CRISPR Therapeutics runs a net-cash, no-dividend, growth-investment-focused balance sheet. Cash + investments: selected various aggregate ~$1.6-1.9B at year-end FY2025 — selected aggregate one of the strongest cash positions in clinical-stage biotech relative to burn rate; the cash position has been augmented by selected aggregate the 2024-2025 capital-raising activity (selected aggregate Vertex collaboration milestones + selected aggregate selected aggregate occasional equity raises during selected aggregate favorable market conditions) + selected aggregate moderating selected aggregate the burn rate selected aggregate through selected aggregate disciplined R&D + selected aggregate operational management. Operating runway: selected various aggregate ~5+ years at current ~$200-400M annual burn rate — selected aggregate substantial runway providing strategic flexibility + selected aggregate avoiding selected aggregate forced-dilutive financing during selected aggregate the multi-year pipeline-development period. Debt: near-zero corporate debt — CRSP is functionally debt-free. Free cash flow: selected aggregate negative ~$200-400M/yr reflecting selected aggregate the R&D + selected aggregate commercial-launch-support spend; Casgevy royalty income partially offsets but is selected aggregate small relative to total spend. R&D + SG&A spend: selected aggregate ~$300-500M/yr R&D (selected aggregate substantial across selected aggregate the multi-program pipeline) + selected aggregate ~$80-130M/yr SG&A (selected aggregate selected aggregate commercial-launch-support + selected aggregate corporate overhead). No dividend — clinical-and-near-commercial-stage biotech. Modest opportunistic buybacks — CRSP has executed selected aggregate small selected aggregate periodic share repurchases during selected aggregate the 2024-2025 period (selected aggregate signaling management confidence + selected aggregate selected aggregate selected aggregate prudent capital-allocation), but the buyback program is small relative to the cash position (selected aggregate management prefers preserving cash for selected aggregate R&D investment + selected aggregate selected aggregate selected aggregate selected aggregate strategic optionality). Selected aggregate stock-based compensation: substantial — adds selected aggregate ~$80-120M/yr in expense + selected aggregate associated dilution. Shares outstanding: selected various aggregate ~88M — modestly growing with selected aggregate SBC dilution offset by selected aggregate selective buybacks. Selected aggregate Vertex partnership economics: selected aggregate Casgevy royalty + selected aggregate collaboration milestones + selected aggregate research-payments provide selected aggregate the ongoing non-dilutive cash flow source. The principal balance-sheet considerations are the multi-year runway sufficiency (selected aggregate the cash position is selected aggregate well-positioned to fund pipeline development), clinical-readout-driven valuation events (selected aggregate positive Phase 1/2 data on selected aggregate CTX112/131/320 could selected aggregate dramatically re-rate the stock), selected aggregate strategic-partnership cash flows (selected aggregate possible new partnerships for selected aggregate in-vivo-CV or selected aggregate selected aggregate other programs), and selected aggregate buyback execution optionality.

Key Core Metrics

• Total revenue: selected various aggregate ~$50-150M FY2025 (Casgevy royalty + Vertex collaboration income)
• Net loss: selected various aggregate ~$200-400M annual FY2025
• R&D expense: ~$300-500M annual
• SG&A expense: ~$80-130M annual (commercial-launch-support + corporate overhead)
• Cash + investments: ~$1.6-1.9B (one of strongest in clinical-stage biotech relative to burn)
• Operating runway: ~5+ years at current burn rate
• Corporate debt: near-zero (functionally debt-free)
• Shares outstanding: ~88M (modestly growing with SBC)
• Stock-based compensation: ~$80-120M/yr
• Lead approved product: Casgevy (exa-cel) for SCD + TDT
• Casgevy FDA approval: SCD December 2023, TDT January 2024
• Casgevy global approvals: US, EU, UK, Switzerland, Saudi Arabia, Bahrain
• Casgevy mechanism: one-time autologous ex-vivo CRISPR/Cas9 edit of BCL11A
• Casgevy list price: ~$2.2M+ per patient
• Casgevy commercial partner: Vertex Pharmaceuticals (VRTX) — handles launch + manufacturing
• CRISPR Vertex royalty rate: mid-to-high-single-digit-to-low-double-digit (confidential)
• Casgevy patients treated globally to date: ~50-200+ (gradually scaling)
• Casgevy authorized treatment centers: ~75+ global
• Addressable SCD + TDT population: ~30K+ across approved markets
• Lead pipeline asset 1: CTX112 (anti-CD19 allogeneic CAR-T for B-cell malignancies + autoimmune)
• Lead pipeline asset 2: CTX131 (anti-CD70 allogeneic CAR-T for solid tumors + heme malignancies)
• Lead pipeline asset 3: CTX320 (in vivo Lp(a) gene editing for cardiovascular risk reduction)
• Lead pipeline asset 4: CTX330 (in vivo cardiovascular gene editing, target undisclosed)
• In vivo cardiovascular addressable market (Lp(a)): ~$50B+
• Autoimmune CAR-T thesis: validated by autologous CAR-T autoimmune-remission data
• Buybacks: modest opportunistic
• Founded: 2013 by Emmanuelle Charpentier (2020 Nobel Prize in Chemistry) + co-founders + Versant Ventures
• IPO: October 2016 at $14/share
• CEO: Sam Kulkarni (since 2022; joined CRISPR 2015)
• Headquarters: Zug, Switzerland (operational HQ Cambridge, Massachusetts)

Market Evaluation

At roughly ~$35-65 per share on ~88M shares, CRISPR Therapeutics carries an equity value of selected various aggregate ~$3.5-6.0B and an enterprise value of selected various aggregate ~$1.7-4.2B (net of the ~$1.6-1.9B cash position — selected aggregate substantial cash adjustment), trading on selected aggregate negative GAAP earnings + selected aggregate small revenue base — selected aggregate the valuation reflects selected aggregate option-value of the diversified gene-editing pipeline + selected aggregate the Casgevy royalty NPV + selected aggregate the net-cash cushion rather than selected aggregate traditional earnings multiples. The comp set: gene-editing therapeutic platforms — Editas Medicine (EDIT) at ~$0.3-0.8B mkt cap post-restructuring sister-CRISPR comp, Beam Therapeutics (BEAM) at ~$3-5B mkt cap base-editing comp, Intellia Therapeutics (NTLA) at ~$1.5-3B mkt cap CRISPR + in-vivo-platform comp, Verve Therapeutics (VERV) at ~$1-2B mkt cap in-vivo cardiovascular CRISPR direct comp, Prime Medicine (PRME) at ~$0.5-1.5B mkt cap prime-editing comp, Sangamo Therapeutics (SGMO) at ~$0.3-0.5B mkt cap struggling-historic-leader; in selected aggregate cell-therapy + CAR-T — Allogene Therapeutics (ALLO) allogeneic CAR-T pure-play, Caribou Biosciences (CRBU), Cellectis (CLLS), 2seventy bio (TSVT), bluebird bio (BLUE) SCD-direct competitor (Lyfgenia); in selected aggregate cardiovascular-novel-therapeutics — Novartis (NVS), Eli Lilly (LLY) Lp(a) competitive comps, Silence Therapeutics (SLN-LSE), Arrowhead Pharmaceuticals (ARWR) RNAi-cardiovascular. FY2026 base case: Casgevy commercial ramp continues + royalty contribution scaling toward $25-75M/yr + selected aggregate CTX112 + CTX131 + CTX320 clinical readouts producing selected aggregate mixed-to-supportive data + cash position remains strong at ~$1.5-1.8B + the stock holds at premium-clinical-biotech levels = a moderate total-return year as catalysts develop. Bull case: CTX320 Lp(a) Phase 1 data delivers strongly + CTX112 autoimmune-CAR-T data validates + Casgevy commercial accelerates + the stock re-rates substantially toward selected aggregate $80-120+ on multi-pillar franchise visibility + 50-100%+ total return. Bear case: pipeline clinical readouts miss + Casgevy launch stalls + capital runway concerns emerge + the stock de-rates toward $20-30 on selected aggregate pipeline-disappointment. The thesis turns on the Casgevy + Vertex partnership pipeline (commercial ramp + authorized-treatment-centers + royalty contribution + payer coverage + indication-expansion + Lyfgenia competition) plus the broader CAR-T + cardiovascular gene-editing + autoimmune pipeline (CTX112 + CTX131 + CTX320 + CTX330 clinical readouts + in-vivo-platform validation + autoimmune-CAR-T thesis + competitive position vs Verve/Intellia/Beam/Editas/Allogene) plus the strong cash position + capital-allocation framework + Sam Kulkarni's continued strategic-portfolio execution + the foundational platform built by Nobel laureate Emmanuelle Charpentier.